Dr. Jane
February 1, 2023
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Clearmind Medicine Inc. (NASDAQ: CMND) today announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the “trial” ) resulted in …
Clinically relevant translational research Despite recent developments of sophisticated and novel methods in preclinical research, there is still a deficiency of models that can reliably replicate patient groups sufficiently to enable benefits from PM to be realised. Only a small proportion of preclinical research performed prior to clinical trials translates into clinical benefit in humans , for instance in Alzheimer’s …
July 7, 2022 — Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced the publication of preclinical research in the July 6 issue of Science Translational Medicine. The article, titled “Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse …
NEW YORK, May 5, 2022 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico’s growing portfolio of synthetic lethality assets in development. …
NEW YORK, May 6, 2022 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The MAT2A program is part of Insilico’s growing portfolio of synthetic lethality assets in …
Baylor College of Medicine to Present eFFECTOR Therapeutic-Driven Preclinical Data to Support the Development of Zotatifin in Triple Negative Breast Cancer at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 Details Category: Small Molecules Posted on Saturday, October 09, 2021 11:01 AM Hits: 36 • Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem cell signaling pathways …
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem cell signaling pathways • Induces beneficial changes in the tumor microenvironment by increasing the production of proteins involved in the interferon-α and interferon-γ pathways • Proven statistically significant prolongation of survival in combination with carboplatin and everolimus (mTOR inhibitor) SAN DIEGO, October 07, 2021 (GLOBE NEWSWIRE) – eFFECTOR Therapeutics …
